Physician profile
Peter Qiang Chen
NPI 1740275007
$2,394.00
in general payments reported to CMS, 2019-2025
22 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $31.27 · 2021: $127 · 2022: $484 · 2023: $571 · 2024: $485 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $367.21 | 2021-2025 | Cequa |
| Alcon Vision LLC | $281.18 | 2019-2025 | Rocklatan, Simbrinza, Precision7 |
| Bausch & Lomb Americas INC. | $246.03 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $234.59 | 2019-2023 | |
| Abbvie INC. | $230.13 | 2022-2025 | Durysta |
| Oyster Point Pharma, INC. | $225.17 | 2023-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Vision Care, INC. | $154.32 | 2019-2023 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.01 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $77.64 | 2024-2025 | Xdemvy |
| Allergan, INC. | $71.60 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $61.37 | 2019-2021 | |
| Harrow Eye, LLC | $53.87 | 2024 | Vevye |
| Biotissue Holdings INC. | $49.40 | 2022-2023 | |
| Coopervision INC. | $40.17 | 2019-2022 | |
| Dompe US, INC. | $40.02 | 2022-2024 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $40.00 | 2019 | |
| Thea Pharma INC. | $38.79 | 2023-2025 | Iyuzeh |
| Coherus Oncology, INC. | $25.19 | 2023 | |
| Shire North American Group INC | $21.37 | 2019 | |
| Sight Sciences, INC. | $20.69 | 2022 | |
| Eyevance Pharmaceuticals LLC | $18.92 | 2019 | |
| Astellas Pharma US INC | $18.33 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.